Patents by Inventor Philip L. Simon

Philip L. Simon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TNF inhibition
    Patent number: 5547979
    Abstract: Derivatives of 2-pyrrolidinones are described which inhibit the production of TNF and are useful in the treatment of disease states mediated or exacerbated by TNF production.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: August 20, 1996
    Assignee: SmithKline Beecham
    Inventors: Siegfried B. Christensen, IV, Klaus M. Esser, Philip L. Simon
  • TNF inhibitors
    Patent number: 5420154
    Abstract: Derivatives of 2-pyrrolidinones are described which inhibit the production of TNF and are useful in the treatment of disease states mediated or exacerbated by TNF production.
    Type: Grant
    Filed: March 30, 1992
    Date of Patent: May 30, 1995
    Assignee: SmithKline Beecham Corp.
    Inventors: Siegfried B. Christensen, IV, Klaus M. Esser, Philip L. Simon
  • Phenylalkyl oxamides
    Patent number: 5393788
    Abstract: Novel oxamide derivatives are described which inhibit the production of TNF and are useful in the treatment of disease states mediated or exacerbated by TNF production. The compounds of the present invention are also useful as inhibitors of PDE IV and are therefor useful in the treatment of disease states mediated or exacerbated thereby.
    Type: Grant
    Filed: March 2, 1993
    Date of Patent: February 28, 1995
    Assignee: SmithKline Beecham Corporation
    Inventors: Paul E. Bender, Siegfried B. Christensen, IV, Klaus M. Esser, Cornelia J. Forster, Michael D. Ryan, Philip L. Simon
  • Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
    Patent number: 5317019
    Abstract: A method of inhibiting the production of interleukin-1 by monocytes and/or macrophages in a human in need thereof which comprises administering to such a human an effective, interleukin-1 production inhibiting amount of a diaryl-substituted imidazole fused to a second heterocyclic ring containing a nitrogen bridgehead atom wherein said second ring may also contain sulfur, oxygen or an additional nitrogen atom, and may contain additional unsaturation.This invention relates to a method of inhibiting the production of Tumor Necrosis Factor (TNF) by monocytes or macrophages in a human in need thereof which comprises administering to such mammal an effective, TNF production inhibiting amount of a compound of Formula (I) as described herein. The compounds of Formula (II) are generally described as diaryl-substituted imidazole fused to a second heterocyclic ring containing a nitrogen bridgehead wherein said ring may also contain sulfur, oxygen, or an additional nitrogen atom, and may contain additional unsaturation.
    Type: Grant
    Filed: December 12, 1991
    Date of Patent: May 31, 1994
    Assignee: SmithKline Beecham Corp.
    Inventors: Paul E. Bender, Don E. Griswold, Nabil Hanna, John C. Lee, Bartholomew J. Votta, Philip L. Simon, Alison M. Badger, Klaus M. Esser